E

Corporate Research Report: Envisagenics



Company Overview



Name:


Envisagenics

Mission of the Company:


Envisagenics leverages Artificial Intelligence (AI) and Machine Learning (ML) to unlock the therapeutic potential of RNA.

Founding:


  • Year Founded: 2014

  • Founding Origin: Spinout of Cold Spring Harbor Laboratory (CSHL)


Key People:


  • Maria Luisa Pineda, PhD

  • Role: Co-Founder & CEO

  • Background: Awarded endowment from the Goizueta Foundation, NIH fellowship recipient, Doctorate from Cold Spring Harbor Laboratory, investment experience in tech and life-sciences startup companies.

  • Martin Akerman, PhD

  • Role: Co-Founder & CTO

  • Background: Inventor of SpliceCore®, trained in RNA splicing, PhD in Bioinformatics from Technion.

  • Board Members:

  • Michael Grissinger, MBA

  • Executive BD, Johnson & Johnson

  • Grant Verstandig

  • Co-Founder, Red Cell Partners; Founder, Rally Health

  • Scientific and Business Advisory Board:

  • Adrian Krainer, PhD

  • Professor & Program Chair, Cold Spring Harbor Laboratory

  • Michael Q Zhang, PhD

  • Professor & Director, Center for Systems Biology, University of Texas at Dallas; Guest Professor, Tsinghua University

  • Omar I. Abdel-Wahab, MD

  • Hematologic Oncologist, Memorial Sloan Kettering Center for Hematologic Malignancies

  • Sudhir Agrawal, D.Phil, FRSC

  • Founding Scientist, Idera Pharmaceuticals; Visiting Professor, University of Massachusetts Medical School


Headquarters:


30-02 48th Ave, Suites 140 and 150, Long Island City, New York NY 11101

Number of Employees:


No information is available

Revenue:


No information is available

Known For:


Envisagenics is known for its SpliceCore® software platform that accelerates the discovery of splicing-derived drug targets for RNA therapeutics.

Products



SpliceCore® Platform


  • Description: An AI/ML-powered platform that transforms RNA sequencing data to discover novel drug targets.

  • Key Features:

  • Identifies new targets for RNA therapeutics.

  • Validates splicing events and drug targets with high accuracy.

  • Provides a large search space for target discovery using an exon-centric approach.

  • Excels in experimental validation and disease-specific splicing events.


SpliceIO™


  • Description: The immunotherapeutic branch of SpliceCore®.

  • Key Features:

  • Identifies tumor-specific neoepitopes.

  • Enables development of antibody-based modalities for cancer treatment.


Recent Developments



New Products Launched:


  • SpliceCore® Platform: Continues to evolve, integrating novel features for better RNA therapeutic discoveries.

  • SpliceIO™: Developed as a specialized module for identifying tumor-specific biomarkers and neoepitopes.


New Features:


  • Identification and validation of splice-switching oligonucleotides (SSOs) for targeted therapy in several cancer types.

  • Enhanced cloud architecture for scalable processing of massive RNA-seq data.


Strategic Collaborations:


  • Cancer Research Horizons and Queen Mary University of London (Dec 13, 2022): Collaboration to explore RNA splicing in hematopoietic cancers.

  • Bristol Myers Squibb (BMS) (Nov 29, 2022): Partnership for accelerated discovery and development of oncology therapeutic candidates.

  • Lung Cancer Initiative at Johnson & Johnson: Ongoing research program announced earlier.

  • Collaboration with Biogen (May 13, 2021): Advanced research on RNA splicing.

  • Collaboration with Cancer Research Horizons: To leverage SpliceCore® for expanded drug target discovery and development.


Notable Achievements:


  • Publication in Molecular Systems Biology (April 25, 2024): Validation of the SpliceCore® platform’s efficacy in Triple Negative Breast Cancer (TNBC).

  • Series A Financing (Sept 29, 2021): Raised funds to scale AI-powered RNA splicing drug discovery platform.

  • Awards and Grants:

  • National Institutes of Health (NIH) SBIR Phase II Grant of $1.5M.

  • Multiple SBIR grants from National Cancer Institute (NCI).


Press Coverage:


  • Widespread Recognition: Featured in media outlets such as Business Wire, New York Business Journal, and Innovate Long Island for its innovative AI applications in drug discovery.

  • Awards:

  • Named North American Winner of Innovate AI Competition (May 1, 2018).

  • $2.35M seed round closure launching SpliceCore™ Platform (Nov 28, 2017).


Conclusion



Contact Information:


  • General: info@envisagenics.com

  • Partnership: partner@envisagenics.com

  • Careers: careers@envisagenics.com


_Last updated: 2024_




This report encapsulates key information about Envisagenics, focusing on its mission, innovative products, and recent collaborative advancements.